Olfaction in Parkin-associated Parkinson disease
Another enigma
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Impairment of olfactory function is commonly seen in neurodegenerative diseases such as Parkinson disease (PD), Alzheimer disease, and Huntington disease, but also occurs during normal aging. Therefore, it is not too surprising that in sporadic PD (SPD), olfactory impairment can appear both before and after the onset of motor dysfunction. Nonetheless, in PD, the severity of the olfactory impairment seems to correlate with the severity of motor symptoms, although not in a linear fashion.
Interestingly, olfactory dysfunction in PD is independent of disease stage and disease duration but is dependent on disease subtype—it is more severe in the rigidity-bradykinesia–predominant form than in the tremor-predominant form of PD.1,2 Olfactory dysfunction is also independent of dopaminergic therapy, suggesting that deficits in other neurotransmitter systems contribute to olfactory dysfunction. Indeed, neuropathologic studies of the olfactory system in PD reveal that even though there is significant neuronal loss, dopaminergic neurons in the olfactory bulb are not affected by the neurodegenerative process and do not exhibit Lewy bodies (LB).3 Somewhat surprisingly, one study reported an increase in the numbers of dopaminergic neurons in patients with PD compared to controls.4
Given the extensive interactions of the olfactory system with its environment, early hypotheses to explain olfactory system dysfunction in neurodegenerative disease in general, …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
Dr. Kathleen Digre and Dr. Kendra Pham
► Watch
Alert Me
Recommended articles
-
Articles
Olfaction in Parkin heterozygotes and compound heterozygotesThe CORE-PD studyR.N. Alcalay, A. Siderowf, R. Ottman et al.Neurology, December 29, 2010 -
Articles
Is olfactory impairment in Parkinson disease related to phenotypic or genotypic characteristics?D. Verbaan, S. Boesveldt, S. M. van Rooden et al.Neurology, December 01, 2008 -
Articles
A multidisciplinary study of patients with early-onset PD with and without parkin mutationsE. Lohmann, S. Thobois, S. Lesage et al.Neurology, November 05, 2008 -
Articles
Early-onset parkinsonism associated with PINK1 mutationsFrequency, genotypes, and phenotypesV. Bonifati, C. F. Rohé, G. J. Breedveld et al.Neurology, July 11, 2005